| pubmed-article:11818468 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11818468 | lifeskim:mentions | umls-concept:C0019704 | lld:lifeskim |
| pubmed-article:11818468 | lifeskim:mentions | umls-concept:C0205470 | lld:lifeskim |
| pubmed-article:11818468 | lifeskim:mentions | umls-concept:C2587213 | lld:lifeskim |
| pubmed-article:11818468 | pubmed:dateCreated | 2002-1-30 | lld:pubmed |
| pubmed-article:11818468 | pubmed:abstractText | By destroying CD4+ T cells, human immunodeficiency virus-1 (HIV-1) infection results in immunodeficiency and the inability of the immune system to contain the virus in most individuals. Although treatment of HIV-1 infection with potent antiretroviral medications has resulted in enormous clinical benefit, there is a growing recognition of the limitations of this therapy. As a result, novel approaches to treating HIV-1 infection are being considered. One such strategy is immunotherapy, which seeks to boost immune responses against HIV-1 and control the virus. This approach is based on studies of other viruses in which a coordinated immune response contains the chronic infection. Recent studies show that CD4+ helper responses, CD8+ T cell activity, and antibodies may contribute to control of the virus without antiretroviral therapy in some HIV-positive individuals. Based on this understanding of the immunologic correlates of control of HIV-1, exciting new immunotherapeutic strategies for HIV-1 infection are being designed and tested. | lld:pubmed |
| pubmed-article:11818468 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11818468 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11818468 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11818468 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11818468 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11818468 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11818468 | pubmed:issn | 0066-4219 | lld:pubmed |
| pubmed-article:11818468 | pubmed:author | pubmed-author:WalkerBruce... | lld:pubmed |
| pubmed-article:11818468 | pubmed:author | pubmed-author:GandhiRajesh... | lld:pubmed |
| pubmed-article:11818468 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11818468 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:11818468 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11818468 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11818468 | pubmed:pagination | 149-72 | lld:pubmed |
| pubmed-article:11818468 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:11818468 | pubmed:meshHeading | pubmed-meshheading:11818468... | lld:pubmed |
| pubmed-article:11818468 | pubmed:meshHeading | pubmed-meshheading:11818468... | lld:pubmed |
| pubmed-article:11818468 | pubmed:meshHeading | pubmed-meshheading:11818468... | lld:pubmed |
| pubmed-article:11818468 | pubmed:meshHeading | pubmed-meshheading:11818468... | lld:pubmed |
| pubmed-article:11818468 | pubmed:meshHeading | pubmed-meshheading:11818468... | lld:pubmed |
| pubmed-article:11818468 | pubmed:meshHeading | pubmed-meshheading:11818468... | lld:pubmed |
| pubmed-article:11818468 | pubmed:meshHeading | pubmed-meshheading:11818468... | lld:pubmed |
| pubmed-article:11818468 | pubmed:meshHeading | pubmed-meshheading:11818468... | lld:pubmed |
| pubmed-article:11818468 | pubmed:meshHeading | pubmed-meshheading:11818468... | lld:pubmed |
| pubmed-article:11818468 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11818468 | pubmed:articleTitle | Immunologic control of HIV-1. | lld:pubmed |
| pubmed-article:11818468 | pubmed:affiliation | Partners AIDS Research Center and Infectious Diseases Division, Massachusetts General Hospital and Division of AIDS, Harvard Medical School, Boston, Massachusetts 02114, USA. rgandhi@partners.org | lld:pubmed |
| pubmed-article:11818468 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11818468 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11818468 | lld:pubmed |
